PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Merker, Ludwig
TI  - Reductions in HbA1c and Weight in Type 2 Diabetics with the Empagliflozin Add-On Regimen
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 15--17
VI  - 14
IP  - 20
4099  - http://mdc.sagepub.com/content/14/20/15.short
4100  - http://mdc.sagepub.com/content/14/20/15.full
AB  - Empagliflozin is a potent and selective inhibitor of sodium glucose cotransporter 2. This article discusses an extension study, the Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes study [EMPA-REG EXTEND MET; NCT01289990], assessed the long-term safety, tolerability, and efficacy of the empagliflozin add-on regimen.